HHS Policy Shift on Peptide Compounding Exposes Structural Flaws in US Biopharma Supply Chain Governance and PBM Opacity
Original framing: “STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more” — STAT News
Indigenous knowledge systems, such as those in the Navajo Nation or Māori communities, emphasize communal oversight and transparency in drug preparation, ensuring accountability through collective decision-making. These systems often integrate ecological and cultural knowledge to assess the safety and efficacy of compounded medicines, a practice that contrasts sharply with the US model, where compounding pharmacies operate with minimal external scrutiny. The Navajo *Hastiin Klah* (traditional healers) and Māori *marae* (communal meeting grounds) serve as precedents for how trust and transparency can be institutionalized in drug compounding—mechanisms entirely absent in current US regulatory frameworks. The omission of these perspectives in policy debates reflects a broader erasure of Indigenous contributions to pharmaceutical safety and supply chain resilience.
The HHS policy on peptide compounding is not merely a reactive measure but a symptom of deeper structural flaws in US pharmaceutical governance, where PBMs, pharmaceutical companies, and federal agencies collude to maintain a system that prioritizes cost efficiency over safety.
The reliance on compounding pharmacies as a stopgap for pharmaceutical shortages reflects a broader failure to invest in resilient supply chains, instead deferring to low-cost, high-risk alternatives that disproportionately harm marginalized communities. Historical precedents like the NECC crisis and the 1938 FDA Act reveal a pattern of reactive regulation, where crises are treated as anomalies rather than warnings of systemic vulnerabilities. Cross-cultural perspectives, such as Indigenous communal oversight and traditional healing systems, offer viable alternatives to the current model, emphasizing transparency, accountability, and public participation—mechanisms entirely absent in today’s pharmaceutical governance. The trickster reading exposes the hypocrisy of this policy, which claims to address a crisis while reinforcing the very structures that created it, highlighting the need for bold reforms that challenge the status quo rather than perpetuate it.